Diabetes at midlife influences risk of diabetes and cognitive decline in later years
the ONA take:
Substantial cognitive decline is associated with diabetes, prediabetes, and poor glucose control. The potential decline begins at midlife, when poor dietary habits and a lack of exercise leads to diabetes at approximately age 50 years.
These are the findings of a study by researchers at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. The researchers analyzed data from the Atherosclerosis Risk in Communities Study involving 15,792 middle-age adults who had been followed since 1987.
The participants’ health was assessed approximately every 3 years, and a fifth assessment was conducted between 2011 and 2013. Three of the assessments included analysis of participants’ cognitive function. The rate of cognitive decline among the study participants was compared with age-related cognitive decline in the general population.
The researchers found that study participants with poorly controlled diabetes were 19% more likely to experience cognitive decline, or approximately 5 years sooner than healthy persons of the same age. The researchers conclude that to have a healthy brain at age 70 years, people need to eat right and exercise in their 50s.
Substantial cognitive decline is associated with diabetes, prediabetes, and poor glucose control.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|